Mohamad Adham Salkeni, MD, FRCPC earned his medical degree from the University of Damascus. He then completed his residency in internal medicine at St. Louis University and fellowship in hematology and oncology at the University of Cincinnati. During his medical training, he was engaged in bench and translational research investigating inflammatory modulation of the blood-brain barrier in vivo, published in the Journal of Neuroimmune Pharmacology; and established a tumor-informed assay for detecting circulating mutant DNA of brain cancer, published in the Journal of Neuro-Oncology. Following training completion, he joined West Virginia University as an Assistant Professor and was later promoted to Associate Professor, where he also served as Medical Director for the Clinical Trials Research Unit and Co-Chair of the Breast Cancer Leadership Committee. Interested in early drug development, Dr. Salkeni elected to move on to the National Cancer Institute, National Institutes of Health (NCI/NIH) in Bethesda, Maryland, where he completed a fellowship in Advanced Developmental Therapeutics. During his time spent at the NCI, he participated in concept development and design of early phase clinical trials of novel immunotherapeutics and small molecules, and authored a book chapter on resistance mechanisms to immunotherapy.
Dr. Salkeni is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). Dr. Salkeni joined Virginia Cancer Specialists as a Clinical Investigator in Phase 1 cancer clinical trials, in collaboration with NEXT Oncology.
In his spare time, he enjoys swimming and spending time outdoors with family.
